Project Grant R24AI194877
Award Date 8/20/25
Completion Date 7/31/30
Dollars Obligated $846K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Child Health and Human Development (NICHD) awarded a $2,207,322 Project Grant under the Child Health and Human Development Extramural Research program (CFDA 93.865) to the University of Nebraska Medical Center to develop dose flexible, ultra-long-acting prodrug formulations for antiretroviral therapy (ART) in pediatric HIV patients. The goal is to create a complete every 6-month integrase strand transfer inhibitor (INSTI)-based ART regimen, including bictegravir,...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,414,502 to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on assessing the variability in antiretroviral (ARV) drug penetration within tissues as a potential factor contributing to the persistence of HIV during treatment. The research aims to leverage advanced imaging techniques,...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $703,675 Project Grant (CFDA 93.279) to the University of North Carolina at Chapel Hill (UNC-CH) for the project "Transcriptional Inactivation of the CNS HIV Reservoir with Tat-Targeting Lipid Nanoparticles." This grant aims to develop lipid nanoparticles containing gene-editing tools that can inactivate the HIV Tat gene in microglial cells, the primary HIV reservoir in the central...
- This $418,625 Project Grant awarded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to Drexel University supports research to develop a novel approach using RNA interference (RNAi) to silence HIV transcription in myeloid cells. The goal is to functionally eliminate the HIV reservoir in the central nervous system by inducing a stable heterochromatic state to block proviral transcription and production of new virions in chronically infected...
- This federal Project Grant award of $819,603 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to implement novel strategies for long-acting antiretroviral therapy (ART) among people with criminal legal involvement (CLI) living with HIV. The project, titled "INSIDE START: Implementation of Novel Strategies for Long-Acting ART - People with Criminal Legal Involvement (CLI)," will be...
- The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $999,991 Project Grant to Tendel Therapies Inc. on August 13, 2025. The grant supports the development of an HIV reservoir-depletion agent, BSAB-98, a bispecific antibody that targets CCR5-expressing cells for elimination. Preclinical studies in infant rhesus macaques showed over 50% remission of simian immunodeficiency virus (SIV) after BSAB-98...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing the HIV-1 viral reservoirs that persist even under antiretroviral therapy (ART). The 2-year project aims to identify the cellular sources and genetic diversity of the HIV-1 reservoirs, as well as study the sources and characteristics of the residual viremia...
- This $1,144,344 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a novel gene therapy approach to eliminate the HIV/SIV reservoir in the central nervous system of methamphetamine-exposed rhesus macaques on antiretroviral therapy. The research will use a specialized AAV vector (R2MAC) capable of penetrating the blood-brain barrier to deliver multiplex CRISPR/Cas editors targeting the viral...
- The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $687,416 Project Grant to the J. David Gladstone Institutes in San Francisco, California. The grant is for a research project titled "Targeted Small Molecule Recruitment to Suppress the HIV Transcriptionally Active Reservoir" and runs from May 15, 2025 to March 31, 2030. The key objectives of this research project are to develop therapeutically effective...